Latest 5 articles from heartwire
- Sen Grassley questions top medical schools about ghostwriting
Nov 20, 2009 13:15 EDT - Stroke incidence related to PCI steady over 15 years
Nov 20, 2009 13:00 EDT - ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
Nov 19, 2009 14:00 EDT - Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EDT - EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EDT
RE-LY: Patient preference based on the data
Posted Sep 11, 2009
at 10:05 AM, EDT
by Seth Bilazarian
Our academic colleagues and trialists prepare and execute trials to evaluate MACE and safety. Critical of course, but after the trial is over practioners need to assess the practical aspects of therapies which include non-MACE considerations like patient nuisance factors: diet restrictions, venipuncture cost and discomfort, and difficulty in reversing anticoagulation. If you needed oral anticoagulation with atrial fibrillation would you prefer warfarin over dabigatran?
See:
RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib
Best of Barcelona: PLATO and RE-LY
RE-LY: An obituary for Warfarin?
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Previous postsBillets précédents
ARBITER 6-HALTS: What are the clinical implications?
No commentsAucun commentaire |
Posted Nov 18, 2009
at 12:45 PM, EDT by Seth Publié le 11.18.2009 à 12h45 par Seth
at 12:45 PM, EDT by Seth Publié le 11.18.2009 à 12h45 par Seth
AHA late-breaking clinical trial: RAPTOR -- femoral to radial access for PCI
No commentsAucun commentaire |
Posted Nov 15, 2009
at 07:50 AM, EDT by Seth Publié le 11.15.2009 à 07h50 par Seth
at 07:50 AM, EDT by Seth Publié le 11.15.2009 à 07h50 par Seth
Glossy job listings in a hostile healthcare environment
No commentsAucun commentaire |
Posted Oct 28, 2009
at 03:30 PM, EDT by Seth Publié le 10.28.2009 à 15h30 par Seth
at 03:30 PM, EDT by Seth Publié le 10.28.2009 à 15h30 par Seth
Passwords and network security: Is more "less"?
No commentsAucun commentaire |
Posted Oct 21, 2009
at 10:30 AM, EDT by Seth Publié le 10.21.2009 à 10h30 par Seth
at 10:30 AM, EDT by Seth Publié le 10.21.2009 à 10h30 par Seth
From femoral to radial access for PCI: Practical tips and observations for the community based interventional practitioner
No commentsAucun commentaire |
Posted Oct 14, 2009
at 10:45 AM, EDT by Seth Publié le 10.14.2009 à 10h45 par Seth
at 10:45 AM, EDT by Seth Publié le 10.14.2009 à 10h45 par Seth
Also from theheart.org
About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:
- Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
- Practice approaches to the extra clinical issues in dealing with managed care insurers
- Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
- Experiences with restrictions on testing and imaging














CommentsCommentaires